medigraphic.com
Instituto Nacional de Salud Pública

2024, Number 3

<< Back Next >>

salud publica mex 2024; 66 (3)

Prostate cancer in Latin America and the Caribbean: mortality trends from 1997 to 2017 and predictions to 2030

Torres-Roman JS, Valcarcel B, Arce-Huamani MA, Simbaña-Rivera K, Salvador-Carrillo JF, Poterico JA, Quispe-Vicuña C, Alvarez CS, McGlynn KA

Language: English
References: 59
Page: 226-235
PDF size: 350.88 Kb.


ABSTRACT

Objective. To evaluate the mortality rates of prostate cancer in Latin American and the Caribbean (LAC) countries and predict their mortality to 2030. Materials and methods. The data was retrieved from the World Health Organization mortality database. The age-standardized mortality rates for prostate cancer were estimated per 100 000 men between 1997 and 2017 for most LAC countries. The annual percent change was calculated by country and age group. The Nordpred was used to project prostate cancer mortality to 2030. Results. From 1997 to 2017, the countries with the highest mortality rates from prostate cancer were Trinidad and Tobago, Cuba, and Venezuela. For all ages, ten LAC countries presented significant decreases between -0.5 and -2.8%, whereas Brazil, Cuba, Guatemala, and Venezuela showed increases. Mortality by prostate cancer will increase in 2030 due to changes in the structure and size of the population. Conclusions. Despite the decline in statistiprostate cancer mortality rates over the last two decades in most countries in the region, some countries still have very high mortality rates. By 2030, most countries in the region will show overall increases in the number of deaths, mainly due to population size.


REFERENCES

  1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. GlobalCancer Observatory: Cancer Today. Lyon: International Agency forResearch on Cancer, 2020 [cited March 11, 2023]. Available from: https://gco.iarc.fr/today

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2021;71(3):209-49. http://doi.org/10.3322/caac.21660

  3. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent globalpatterns in prostate cancer incidence and mortality rates. Eur Urol.2020;77(1):38-52. https://doi.org/10.1016/j.eururo.2019.08.005

  4. Carioli G, La Vecchia C, Bertuccio P, Rodriguez T, Levi F, Boffetta P, etal. Cancer mortality predictions for 2017 in Latin America. Ann Oncol.2017;28(9):2286-97. http://doi.org/10.1093/annonc/mdx301

  5. Carioli G, Bertuccio P, Malvezzi M, Rodriguez T, Levi F, Boffetta P, et al.Cancer mortality predictions for 2019 in Latin America. Int J Cancer.2020;147(3):619-32. https://doi.org/10.1002/ijc.32749

  6. Torres-Roman JS, Ruiz EF, Martinez-Herrera JF, Mendes-Braga SF, Taxa L,Saldaña-Gallo J, et al. Prostate cancer mortality rates in Peru and its geographicalregions. BJU Int. 2019;123(4):595-601. https://doi.org/10.1111/bju.14578

  7. Quezada AD, Lozada-Tequeanes AL. Time trends and sex differences inassociations between socioeconomic status indicators and overweightobesityin Mexico (2006-2012). BMC Public Health. 2015;15(1):1244.http://doi.org/10.1186/s12889-015-2608-2

  8. World Health Organization. International Classification of Disease andRelated Health Problems: 10th Revision. Geneva: WHO, 1992 [cited March11, 2023]. Available from: https://www.who.int/standards/classifications/classification-of-diseases/list-of-official-icd-10-updates.1

  9. United Nations, Department of Economic and Social Affairs PopulationDivision. World Population Prospects 2022. United Nations, 2022 [citedJanuary 11 2024]. Available from: https://population.un.org/wpp/

  10. World Health Organization. Age Standardization of Rates: A new WhoStandard. WHO, 2001 [cited March 11, 2023]. Available from: https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/gpe_discussion_paper_series_paper31_2001_age_standardization_rates.pdf

  11. National Cancer Institute. Joinpoint regression program. NIH, 2023[cited April 4, 2020]. Available from: https://surveillance.cancer.gov/help/joinpoint

  12. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests forjoinpoint regression with applications to cancer rates. Stat Med.2000;19(3):335-51. https://doi.org/10.1002/sim.811

  13. Bray F, Piñeros M. Cancer patterns, trends and projections inLatin America and the Caribbean: a global context. Salud Publica Mex.2016;58(2):104-17. http://doi.org/10.21149/spm.v58i2.7779

  14. Torres-Roman JS, Ronceros-Cardenas L, Valcarcel B, Bazalar-Palacios J,Ybaseta-Medina J, Carioli G, et al. Cervical cancer mortality among youngwomen in Latin America and the Caribbean: trend analysis from 1997 to2030. BMC Public Health. 2022;22(1):113. https://doi.org/10.1186/s12889-021-12413-0

  15. Mafra-Soares SC, Rodrigues-Dos Santos KM, Gomes de Morais-Fernandes FC, Ribeiro-Barbosa I, Bezerra de Souza DL. Testicularcancer mortality in Brazil: trends and predictions until 2030. BMC Urol.2019;19(1):59. https://doi.org/10.1186/s12894-019-0487-z

  16. Doll R, Payne P, Waterhouse JAH, eds. Cancer incidence in five countries.Vol1. Berlin: Springer-Verlag, 1966.

  17. Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M,Haldorsen T. Prediction of cancer incidence in the Nordic countries: empiricalcomparison of different approaches. Stat Med. 2003;22(17):2751-66.https://doi.org/10.1002/sim.1481

  18. Torres-Roman JS, Valcarcel B, Arce-Huamani MA, Simbaña-Rivera K,Salvador-Carrillo JF, Poterico JA, et al. Supplementary figures from thestudy “Prostate cancer in Latin America and the Caribbean: Mortalitytrends from 1997 to 2017 and predictions to 2030”. Harvard Dataverse,2024. https://doi.org/10.7910/DVN/JZYHZO

  19. Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A.Epidemiology, etiology, diagnosis and treatment of prostate cancer.Asian Pac J Cancer Prev. 2014;15(22):9575-8. https://doi.org/10.7314/apjcp.2014.15.22.9575

  20. Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden inCentral and South America. Cancer Epidemiol. 2016;44(Suppl1):S131-S40.https://doi.org/10.1016/j.canep.2016.06.010

  21. Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, LaVecchia C. Trends in mortality from major cancers in the Americas:1980-2010. Ann Oncol. 2014;25(9):1843-53. https://doi.org/10.1093/annonc/mdu206

  22. Warner WA, Lee TY, Fang F, Llanos AAM, Bajracharya S, Sundaram V, etal. The burden of prostate cancer in Trinidad and Tobago: one of the highestmortality rates in the world. Cancer Causes Control. 2018;29(7):685-97. https://doi.org/10.1007/s10552-018-1038-8

  23. Iser DA, Cobalchini GR, de Oliveira MM, Teixeira R, Malta DC,Naghavi M, Moehlecke-Iser BP. Prostate cancer mortality in Brazil1990-2019: geographical distribution and trends. Rev Soc Bras Med Trop.2022;55(Suppl1):e0277-2021. https://doi.org/10.1590/0037-8682-0277-2021

  24. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, Escamilla-Nuñez C, Vázquez-Salas RA, Campuzano JC, et al. Prostate cancer mortalityaccording to marginalization status in Mexican states from 1980 to2013. Salud Publica Mex. 2016;58(2):179-86. http://doi.org/10.21149/spm.v58i2.7787

  25. Beltran-Ontiveros SA, Fernandez-Galindo MA, Moreno-Ortiz JM,Contreras-Gutierrez JA, Madueña-Molina J, Arambula-Meraz E, et al.Incidence, mortality, and trends of prostate cancer in Mexico from 2000to 2019: results from the Global Burden of Disease Study 2019. Cancers.2022;14(13):3184. https://doi.org/10.3390/cancers14133184

  26. Mikkelsen L, Phillips DE, AbouZahr C, Setel PW, De Savigny D, LozanoR, Lopez AD. A global assessment of civil registration and vital statistics systems:monitoring data quality and progress. Lancet. 2015;386(10001):1395-406. https://doi.org/10.1016/S0140-6736(15)60171-4

  27. Naghavi M, Makela S, Foreman K, O’Brien J, Pourmalek F, Lozano R. Algorithmsfor enhancing public health utility of national causes-of-death data.Popul Health Metr. 2010;8:9. https://doi.org/10.1186/1478-7954-8-9

  28. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, SchmidlinF, et al. Recent trends in prostate cancer mortality show a continuousdecrease in several countries. Int J Cancer. 2008;123(2):421-9. https://doi.org/10.1002/ijc.23520

  29. Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidenceand mortality: global status and temporal trends in 89 countriesfrom 2000 to 2019. Front Public Health. 2022;10:811044. https://doi.org/10.3389/fpubh.2022.811044

  30. Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al.Cancer statistics for the US Hispanic/Latino population, 2021. CA CancerJ Clin. 2021;71(6):466-87. https://doi.org/10.3322/caac.21695

  31. Lortet-Tieulent J, Georges D, Bray F, Vaccarella S. Profiling global cancerincidence and mortality by socioeconomic development. Int J Cancer.2020;147(11):3029-36. https://doi.org/10.1002/ijc.33114

  32. Tourinho-Barbosa RR, Lima-Pompeo AC, Glina S. Prostate cancer inBrazil and Latin America: epidemiology and screening. Int Braz J Urol.2016;42(6):1081-90. https://doi.org/10.1590/S1677-5538.IBJU.2015.0690

  33. Borges dos Reis R, Alías-Melgar A, Martínez-Cornelio A, Neciosup SP,Sade JP, Santos M, Martin-Villoldo G. Prostate Cancer in Latin America:challenges and recommendations. Cancer Control. 2020;27(1). https://doi.org/10.1177/1073274820915720

  34. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. Obesity prevalenceand trends in Latin American countries. Obes Rev. 2001;2(2):99-106. https://doi.org/10.1046/j.1467-789x.2001.00029.x

  35. Popkin BM, Reardon T. Obesity and the food system transformationin Latin America. Obes Rev. 2018;19(8):1028-64. https://doi.org/10.1111/obr.12694

  36. Jiwani SS, Carrillo-Larco RM, Hernández-Vásquez A, Barrientos-Gutiérrez T, Basto-Abreu A, Gutierrez L, et al. The shift of obesity burdenby socioeconomic status between 1998 and 2017 in Latin Americaand the Caribbean: a cross-sectional series study. Lancet Glob Health.2019;7(12):e1644-e54. https://doi.org/10.1016/S2214-109X(19)30421-8

  37. Rivera-Izquierdo M, Pérez de Rojas J, Martínez-Ruiz V, Pérez-GómezB, Sánchez MJ, Khan KS, Jiménez-Moleón JJ. Obesity as a risk factor forprostate cancer mortality: a systematic review and dose-response metaanalysisof 280,199 patients. Cancers. 2021;13(16): https://doi.org/10.3390/cancers13164169

  38. Tzenios N, Tazanios ME, Chahine M. The impact of body mass index onprostate cancer: An updated systematic review and meta-analysis. Medicine.2022;101(45):e30191. https://doi.org/10.1097/MD.0000000000030191

  39. Brown CR, Hambleton I, Hercules SM, Unwin N, Murphy MM, Nigel-Harris E, et al. Social determinants of prostate cancer in the Caribbean:a systematic review and meta-analysis. BMC Public Health. 2018;18:900.https://doi.org/10.1186/s12889-018-5696-y

  40. Tobias-Machado M, Carvalhal GF, Freitas Jr CH, dos Reis RB, ReisLO, Nogueira L, et al. Association between literacy, compliance withprostate cancer screening, and cancer aggressiveness: results from aBrazilian screening study. Int Braz J Urol. 2013;39(3):328-34. https://doi.org/10.1590/S1677-5538.IBJU.2013.03.05

  41. Shavers VL, Underwood W, Moser RP. Race/ethnicity and theperception of the risk of developing prostate cancer. Am J Prev Med.2009;37(1):64-7. https://doi.org/10.1016/j.amepre.2009.03.007

  42. Vapiwala N, Miller D, Laventure B, Woodhouse K, Kelly S, Avelis J, et al.Stigma, beliefs and perceptions regarding prostate cancer among Blackand Latino men and women. BMC Public Health. 2021;21(1):758. https://doi.org/10.1186/s12889-021-10793-x

  43. Taitt HE. Global trends and prostate cancer: a review of incidence,detection, and mortality as influenced by race, ethnicity, and geographiclocation. Am J Mens Health. 2018;12(6):1807-23. https://doi.org/10.1177/1557988318798279

  44. Rubin MA, Demichelis F. The Genomics of Prostate Cancer: emergingunderstanding with technologic advances. Mod Pathol. 2018;31(Suppl1):1-11. https://doi.org/10.1038/modpathol.2017.166

  45. Pilleron S, Soerjomataram I, Soto-Perez-de Celis E, Ferlay J, Vega E,Bray F, Piñeros M. Aging and the cancer burden in Latin America and theCaribbean: Time to act. J Geriatr Oncol. 2019;10(5):799-804. https://doi.org/10.1016/j.jgo.2019.02.014

  46. Mendes-Braga SF, Carvalho de Souza M, Romie de Oliveira R, Gurgel-Andrade EI, de Assis-Acurcio F, Leal-Cherchiglia M. Patient survival andrisk of death after prostate cancer treatment in the Brazilian UnifiedHealth System. Rev Saude Publica. 2017;51:46. https://doi.org/10.1590/S1518-8787.2017051006766

  47. Cayetano-Alcaraz A, Ramírez-Rivera J, Sotomayor de Zavaleta M,Castillejos-Molina R, Gabilondo-Navarro F, Feria-Bernal G, Rodríguez-CovarrubiasFT. Características de los casos incidentes de cáncer de próstataen los últimos 5 años en un hospital de tercer nivel en México. Rev MexUrol. 2016;76(2):76-80. https://doi.org/10.1016/j.uromx.2015.11.007

  48. Villegas-Mejia CR, Chacón-Cardona JA, Sánchez-Villegas T. Sobrevida encáncer de próstata de una población del centro de Colombia. Acta MedColomb. 2015;40(2):101-8. https://doi.org/10.36104/amc.2015.447

  49. Abdel-Rahman O. Assessment of the prognostic value of the 8th AJCCstaging system for patients with clinically staged prostate cancer; A timeto sub-classify stage IV? PLoS ONE. 2017;12(11): e0188450. https://doi.org/10.1371/journal.pone.0188450

  50. Hinata N, Fujisawa M. Racial differences in prostate cancer characteristicsand cancer-specific mortality: an overview. World J Mens Health.2022;40(2):217-27. https://doi.org/10.5534/wjmh.210070

  51. McHugh J, Saunders EJ, Dadaev T, McGrowder E, Bancroft E, Kote-JaraiZ, Eeles R. Prostate cancer risk in men of differing genetic ancestry andapproaches to disease screening and management in these groups. Br JCancer. 2022;126:1366-73. https://doi.org/10.1038/s41416-021-01669-3

  52. Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, etal. Prostate cancer polygenic risk score and prediction of lethal prostatecancer. NPJ Precis Oncol. 2022;6:25. https://doi.org/10.1038/s41698-022-00266-8

  53. Plym A, Penney KL, Kalia S, Kraft P, Conti DV, Haiman C, et al. Evaluationof a multiethnic polygenic risk score model for prostate cancer. J NatlCancer Inst. 2022;114(5):771-4. https://doi.org/10.1093/jnci/djab058

  54. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA,Kote-Jarai Z, et al. Additional SNPs improve risk stratification of a polygenichazard score for prostate cancer. Prostate Cancer Prostatic Dis.2021;24(2):532-41. https://doi.org/10.1038/s41391-020-00311-2

  55. Wei J, Shi Z, Na R, Resurreccion WK, Wang CH, Duggan D, et al.Calibration of polygenic risk scores is required prior to clinical implementation:results of three common cancers in UKB. J Med Genet.2022;59(3):243-7. https://doi.org/10.1136/jmedgenet-2020-107286

  56. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al.Analysis of polygenic risk score usage and performance in diverse humanpopulations. Nat Commun. 2019;10(1):3328. https://doi.org/10.1038/s41467-019-11112-0

  57. Panduro A, Roman S. Personalized medicine in Latin America. FuturMed. 2020;17(5):339-43. https://doi.org/10.2217/pme-2020-0049

  58. Alvarez-Gomez RM, De la Fuente-Hernandez MA, Herrera-MontalvoL, Hidalgo-Miranda A. Challenges of diagnostic genomics in LatinAmerica. Curr Opin Genet Dev. 2021;66:101-9. https://doi.org/10.1016/j.gde.2020.12.010

  59. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, BychkovskyBL, Debiasi M, Liedke PER, et al. Progress and remaining challengesfor cancer control in Latin America and the Caribbean. Lancet Oncol.2015;16(14):1405-38. https://doi.org/10.1016/S1470-2045(15)00218-1




2020     |     www.medigraphic.com